Tuesday, 9 August 2022

Australia's most trusted
source of pharma news

Tuesday, 09 August 2022
Listen to this story 

Top 10 PBS earners face higher bar

Posted 2 August 2022 AM

There was strong growth in the top PBS earners for the second quarter of 2022, but one drug stood out in particular.

Sanofi's Dupixent, used to treat asthma, eczema, atopic dermatitis, and nasal polyps, joined the list in tenth spot after its pre-rebate reimbursement on the R/PBS almost tripled. In Q2 2021 it earned $16.3 million, while in Q2 2022 it brought in $46.0 million.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Sales & Customer Relations (11)

Clinical & Medical, R&D (11)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (15)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.